Table 3.
Treatment add-on patterns among new users of antidiabetic drugs initiated on either metformin or a sulphonylurea.
| Therapy at the index date | Total add-on |
Treatment add-on | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Metformin | Sulfonylureas | Alpha glucosidase inhibitors | £DPP-4 inhibitor | Repaglinide | Thiazolidinediones | ºGLP-1 | 1SGLT2 | Insulin | *P-value | ||
| Total N = 11,228 | 1,017 (9.1%) |
66 (6.5%) | 244 (24.0%) | 14 (1.4%) | 192 (18.9%) | 39 (3.8%) | 13 (1.3%) | 16 (1.6%) | 93 (9.1%) | 340 (33.4%) | – |
| Metformin: ( N = 10,246) | 918 (9.0%) | – | 244 (26.6%) | 14 (1.5%) | 190 (20.7%) | 39 (4.2%) | 13 (1.4%) | 16 (1.7%) | 93 (10.1%) | 309 (33.7%) | 0.432 |
| Comorbidity score (Mean ± SD) | 2.8 ± 2.5 | 3.2 ± 2.8 | 3.6 ± 3.5 | 2.8 ± 2.5 | 3.7 ± 2.9 | 3.5 ± 2.4 | 2.6 ± 2.4 | 2.8 ± 2.2 | 2.6 ± 2.5 | 0.407 | |
| Sulfonylureas: ( N = 982) | 99 (10.1%) | 66 (66.7%) | – | – | 2 (2.0%) | – | – | – | – | 31 (31.3%) | 0.067 |
| Comorbidity score (Mean ± SD) | 2.4 ± 2.5 | 2.8 ± 2.7 | – | – | 3.0 ± 0.0 | – | – | – | – | 2.2 ± 2.3 | 0.143 |
*P-value less of 0.05 was considered to be statistically significant. £ DPP-4, dipeptidyl peptidase-4 inhibitors; ºGLP-1, glucagon-like peptide-1 receptor agonists; 1 SGLT-2, sodium-glucose co-transporter-2 inhibitors.